Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet’s syndrome: case series and literature review
Objectives: This study aimed to investigate the efficacy and safety of tocilizumab (TCZ) in severe and refractory parenchymal neuro-Behçet’s syndrome (p-NBS). Methods: We retrospectively analyzed five patients with p-NBS treated with TCZ in our center between 2013 and 2020, and six cases from litera...
Main Authors: | Jinjing Liu, Dong Yan, Zhimian Wang, Yunjiao Yang, Shangzhu Zhang, Di Wu, Lingyi Peng, Zhichun Liu, Wenjie Zheng |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-11-01
|
Series: | Therapeutic Advances in Musculoskeletal Disease |
Online Access: | https://doi.org/10.1177/1759720X20971908 |
Similar Items
-
The Clinical Features and Risk Factors of Parenchymal Neuro-Behcet’s Disease
by: Dong Yan, et al.
Published: (2019-01-01) -
Unusual Late Onset of Parenchymal Neuro-Behçet Disease
by: Wai Wai Miller, et al.
Published: (2016-01-01) -
Analysis on clinical characteristics of chronic progressive parenchymal neuro-Behçet's syndrome
by: Cui LU, et al.
Published: (2019-06-01) -
Tocilizumab for refractory Castleman’s disease with paraneoplastic pemphigus and Behçet’s disease
by: Vargas Ana, et al.
Published: (2012-07-01) -
Severe panuveitis in neuro-Behçet's disease in Malaysia: a case series
by: Khairuddin, Othman, et al.
Published: (2017)